Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?

被引：0
作者：
Ayman Qasrawi
Waled Bahaj
Lien Qasrawi
Omar Abughanimeh
John Foxworth
Rakesh Gaur
机构：
[1] University of Kentucky,Division of Hematology and Blood & Marrow Transplant, Markey Cancer Center, College of Medicine
[2] University of Missouri-Kansas City,Department of Internal Medicine, School of Medicine
[3] Walmart Pharmacy,undefined
[4] NCI Community Oncology Research Program - Kansas City (NCORP-KC),undefined
[5] KIM Cancer and Blood Center,undefined
来源：
Annals of Hematology | 2019年 / 98卷
关键词：
Cladribine; Acute myeloid leukemia; Remission; Induction; Chemotherapy;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
The combination of cytarabine and an anthracycline has been the standard of care for the induction of remission in acute myeloid leukemia (AML). The response to treatment and survival of adult patients with AML are still variable and depend on multiple factors. Therefore, there have been many efforts to improve the response to treatment and survival rates by either increasing the cytarabine dose or adding a third agent to the standard induction chemotherapy regimen. Unfortunately, attempts to improve response and survival have been mostly unsuccessful. Recent clinical trials and retrospective studies explored the addition of cladribine to standard induction chemotherapy for AML. Some of these studies showed higher rates of complete remission, and one showed improved survival. In this review, we will discuss the antileukemic properties of cladribine and summarize the recent clinical data regarding its incorporation into the induction therapy for adult AML.
引用
收藏
页码：561 / 579
页数：18
相关论文
共 935 条
  • [1] Döhner H(2015)Acute myeloid leukemia N Engl J Med 373 1136-1152
  • [2] Weisdorf DJ(2012)Incidence, survival and prevalence of myeloid malignancies in Europe Eur J Cancer 48 3257-3266
  • [3] Bloomfield CD(2015)Improvements in the early death rate among 9380 patients with acute myeloid leukemia after initial therapy: a SEER database analysis Cancer 121 2004-2012
  • [4] Visser O(2017)Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel Blood 129 424-447
  • [5] Trama A(2004)Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia J Clin Oncol 22 3432-3433
  • [6] Maynadié M(2008)Clinically useful prognostic factors in acute myeloid leukemia Crit Rev Oncol Hematol 66 181-193
  • [7] Stiller C(2009)Anthracycline dose intensification in acute myeloid leukemia N Engl J Med 361 1249-1259
  • [8] Marcos-Gragera R(2015)High doses of daunorubicin during induction therapy of newly diagnosed acute myeloid leukemia: a systematic review and meta-analysis of prospective clinical trials PLoS One 10 e0125612-871
  • [9] De Angelis R(2013)Idarubicin appears equivalent to dose-intense daunorubicin for remission induction in patients with acute myeloid leukemia Leuk Res 37 868-61
  • [10] Mallone S(2016)An update of current treatments for adult acute myeloid leukemia Blood 127 53-3885
12345678910